Legal & General Group Plc purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 1,093,789 shares of the medical research company’s stock, valued at approximately $211,342,000.
A number of other institutional investors also recently modified their holdings of IQV. Financial Freedom LLC bought a new stake in shares of IQVIA during the first quarter valued at approximately $25,000. Ascentis Independent Advisors bought a new position in IQVIA in the 1st quarter worth approximately $25,000. International Assets Investment Management LLC acquired a new position in IQVIA during the 4th quarter worth $27,000. Compass Financial Management LLC bought a new position in IQVIA in the 2nd quarter valued at $27,000. Finally, Gilpin Wealth Management LLC acquired a new stake in shares of IQVIA in the 4th quarter valued at $27,000. 89.62% of the stock is owned by institutional investors.
IQVIA Price Performance
Shares of NYSE IQV opened at $261.57 on Thursday. The company has a fifty day moving average price of $218.41 and a 200 day moving average price of $188.59. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $262.51. The firm has a market cap of $43.05 billion, a PE ratio of 32.45, a PEG ratio of 2.22 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18.
IQVIA declared that its Board of Directors has approved a stock repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board believes its stock is undervalued.
Analysts Set New Price Targets
A number of analysts recently commented on IQV shares. JPMorgan Chase & Co. lifted their price objective on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Morgan Stanley restated an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a research note on Tuesday, July 28th. Robert W. Baird lifted their price target on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Finally, William Blair upgraded shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $241.88.
Check Out Our Latest Report on IQVIA
Insider Buying and Selling at IQVIA
In related news, insider W Richard Staub sold 5,500 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 12,913 shares of company stock valued at $3,098,793 over the last quarter. Insiders own 1.70% of the company’s stock.
About IQVIA
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Stories
- Five stocks we like better than IQVIA
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
